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Deregulated metabolism is a hallmark of cancer. Most normal 
differentiated cells only display low glycolysis rates, of which 
the resulting pyruvate is used to produce ATP through aerobic 
phosphorylation. In contrast, tumor cells have highly increased 
rates of glycolysis, after which the resulting pyruvate is con-
verted to lactate at the expense of efficient energy production. 
This rewired metabolism is likely dictated by the elevated re-
quirements of cancer cells and proliferating cells in general for 
the production of biomass, including fatty acids, amino acids, 
and nucleotides (Vander Heiden et al., 2009). For biosynthe-
sis of nucleotides, an essential intermediate is NAD PH, which 
is produced predominantly by the pentose phosphate pathway 
(PPP). In this pathway, glucose-6-phosphate is converted into 
ribose-5-phosphate, the sugar backbone of nucleotides. In line 
with the elevated requirement for anabolic metabolism, gly-
colytic enzymes, including those functioning in the PPP, are 
found to be up-regulated in various cancers (Durany et al., 
2000). Within the glycolytic pathway, the phosphoglycerate 
mutase enzyme (PGAM, also called PGM), catalyzes the con-
version of 3-phosphoglycerate (3PG) to 2PG (Fig. 1 A). Two 
isoforms of PGAM have been reported: PGAM1 and PGAM2. 
Both isoforms have similar catalytic activity and exist in het-
ero- and homodimers (Mikawa et al., 2014). The substrate of 
PGAM, 3PG, inhibits the enzymatic activity of the PPP com-
ponent 6-phosphogluconate dehydrogenase. As a consequence, 
by converting 3PG into 2PG, PGAM functions to stimulate PPP 
pathway flux and to ensure biosynthesis. This pivotal role in 
coordinating glycolysis with biosynthesis makes PGAM an at-
tractive cancer therapeutic target, as its inhibition may interfere 
with essential needs of cancer cells. Indeed, chemical or genetic 
inhibition of PGAM1 leads to reduced rates of oxidative PPP, 
declined biosynthesis, and was shown to inhibit tumor growth 
in a xenograft tumor model (Hitosugi et al., 2012).
The nucleotides that are produced as as a result of PPP flux 
are required for DNA replication in proliferating cells. DNA 
replication, especially in cancer cells, is not without hazard. 
Unscheduled firing of replication origins caused by oncogene 
activation, as well as increased transcriptional activity leading 
to collisions between the transcription and replication machin-
eries, may stall replication forks and lead to fork collapse (Hills 
and Diffley, 2014). In addition to sufficient building blocks, rep-
licating cells require proper DNA repair to safeguard genome 
stability. Homologous recombination (HR) is critical to mend 
collapsed replication forks. The initial step in HR involves re-
section of DNA ends to create stretches of single-stranded DNA 
(ssDNA). In eukaryotic cells, initiation of DNA end resection 
is governed by the Mre11–Rad50–Nbs1 complex, in conjunc-
tion with the DNA double-strand break end resection factor 
CTBP-interacting protein (CtIP). The resulting ssDNA is ulti-
mately covered with Rad51 filaments, which govern homology 
search and pairing of the ssDNA with the intact template DNA. 
Not only does HR facilitate the repair of collapsed replica-
tion forks, but non-replication–associated DNA double-strand 
breaks can also be repaired with high fidelity using HR, at least 
when cells are in S–G2. Defective HR, for instance, caused by 
cancer-associated mutations in BRCA1/BRCA2, gives rise to 
enhanced sensitivity to agents that perturb DNA replication, in-
cluding poly (ADP-ribose) polymerase (PARP) inhibitors and 
DNA cross-linking agents such as cisplatin (Evers et al., 2010).
In this issue, Qu et al. describe that inactivation of 
PGAM1 results in defective DNA repair through HR. Indeed, 
the researchers observed via SIL AC-based proteomics analy-
ses that PGAM1 depletion is associated with changes in pro-
tein abundance that underscored metabolic rewiring as well 
as with perturbations of the levels of proteins involved in the 
DNA damage response. Notably, PGAM inactivation induced 
down-regulation of the HR component CtIP. Further charac-
terization of the phenotypes of PGAM1-depleted HeLa cells 
showed that PGAM1 depletion leads to enhanced sensitivity to 
DNA damaging agents, including camptothecin, cisplatin, and 
the PARP inhibitor olaparib (Qu et al., 2017). The requirement 
for PGAM1 in HR repair involves its enzymatic activity, as Qu 
et al. (2017) observed that a small molecule inhibitor of PGAM 
or introduction of a catalytically inactive PGAM mutant effec-
tively interfered with HR repair of DNA double-strand breaks.
In accordance with its role in facilitating DNA end resec-
tion, the decreased abundance of CtIP upon PGAM1 depletion 
prevented DNA end resection as well as subsequent steps in 
HR, including replication protein A recruitment and Rad51 fila-
ment formation at sites of DNA damage. Consequently, Qu et al. 
Phosphoglycerate mutase 1 (PGAM1) functions in 
glycolysis. In this issue, Qu et al. (2017. J. Cell Biol. 
https ://doi .org /10 .1083 /jcb .201607008) show that 
PGAM1 inactivation leads to nucleotide depletion, 
which causes defective homologous recombination–
mediated DNA repair, suggesting that targeting 
metabolic enzymes increases cancer cell susceptibility 
to DNA damaging agents.
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(2017) found that genetic or chemical PGAM1 inactivation inter-
fered with functional HR, as judged by repair of I-Sce1–induced 
DNA breaks in a fluoresence-based HR reporter. Previously, 
CtIP levels were shown to be under control of the APC/C-
Cdh1 E3 ubiquitin ligase (Lafranchi et al., 2014). Activation 
of the APC/C-Cdh1 normally occurs in a cell cycle–dependent 
fashion, but can also be triggered in response to DNA damage 
(Bassermann et al., 2008; Wiebusch and Hagemeier, 2010). In 
the context of DNA damage, APC/C-Cdh1 activation requires 
activation of the p53/p21 axis (Wiebusch and Hagemeier, 2010). 
Also in response to PGAM1 inactivation, APC/C-Cdh1 appeared 
responsible for CtIP degradation, as Qu et al. (2017) observed 
that Cdh1 knockdown rescued the decreased CtIP protein levels 
in PGAM1-depleted cells. Of note, CtIP degradation in response 
to PGAM1 depletion did not strictly depend on p53. Knockdown 
of the p53 family member p73 in cells deficient for p53 function, 
or knock down of p53 in p53 wild-type cancer cells, abolished 
p21 levels. In these respective cell lines, chromatin immunopre-
cipitation analyses showed increased p73 or p53 recruitment in 
the promoter region of the p21 gene in PGAM1-depleted cells, 
suggesting p73 and p53 drive p21 up-regulation in response to 
PGAM1 inactivation. In cells in which p53 function is compro-
mised, p73 may functionally compensate for the loss of p53, 
suggesting that p73 provides cell cycle control in TP53 mutant 
cancer cells. In this context, it is of interest that expression 
of PGAM1 itself is under the control of p53 (Kondoh et al., 
2005). Wild-type p53 was reported to block PGAM1 expression, 
whereas expression of a dominant-negative p53 mutant drives 
PGAM1 expression (Kondoh et al., 2005). These effects could 
be attributed to the p53 target MDM-2, which directly ubiquityl-
ates and thereby down-regulates PGAM levels (Mikawa et al., 
2014). Abberant expression of PGAM1 was shown to facilitate 
oncogenic transformation and may in part explain the effects of 
p53 inactivation on tumor cell metabolism (Kondoh et al., 2005).
To assess how PGAM1 inactivation provokes a DNA 
damage response, Qu et al. (2017) examined nucleotide levels. 
In good agreement with a role for PGAM1 in promoting PPP 
flux, PGAM1 inactivation phenocopied the silencing of the PPP 
enzyme 6-phosphogluconate dehydrogenase and led to lower 
levels of deoxynucleoside triphosphates. Very likely, it is the 
ensuing replication stress that resulted in a DNA damage re-
sponse, with consequent transcriptional activation of p53/p73 
and transactivation of their target gene p21.
The APC/C-Cdh1 is negatively regulated by cyclin- 
dependent kinase (CDK) activity, through inhibitory phos-
phorylation of Cdh1 by Cdk2 (Lukas et al., 1999). However, 
Figure 1. PGAM1 inhibition blocks repair of DNA 
breaks through HR. (A) PGAM1 functions in glycol-
ysis by converting 3PG into 2PG. A parallel branch 
of the glycolysis pathway—the PPP—is used to create 
biomass, including nucleotides. Under normal cir-
cumstances, DNA double-strand breaks are repaired 
through HR. A critical first step in HR is Mre11–
Rad50–Nbs1 (MRN)/CtIP–mediated DNA end resec-
tion. (B) When PGAM1 is inactivated, its substrate 
3PG accumulates and inhibits 6-phosphogluconate 
dehydrogenase (6PGD) in the PPP, leading to nucle-
otide pool depletion. The resulting replication stress 
response leads to p53/p73-dependent up-regulation 
of p21 and subsequent activation of the APC/C-
Cdh1 E3 ubiquitin ligase. This leads to ubiquityl-
ation and degradation of CtIP, which precludes 
efficient HR DNA repair.
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up-regulation of the CDK inhibitor p21, as induced by PGAM1 
inactivation, will lead to lower CDK activity, and thereby re-
verses the inhibitory phosphorylation of the APC/C activa-
tor Cdh1. Consequently, p21 up-regulation indirectly leads 
to unscheduled degradation of APC/C-Cdh1 targets. Whether 
APC/C-Cdh1 activation in response to PGAM1 inactivation 
leads to selective degradation of APC/C-Cdh1 targets remains 
unclear. However, the observation that PGAM1 inhibition does 
not dramatically alter cell cycle profiles, as shown by Qu et al. 
(2017) using flow cytometry, suggests that the majority of AP-
C/C-Cdh1 substrates (which include many essential cycle cycle 
regulators) is not significantly affected. If and how the DNA 
damage-activated APC/C-Cdh1 differentially targets substrates 
for ubiquitylation remains to be elucidated.
Therapeutic targeting of metabolism pathway compo-
nents for cancer treatment has been studied for decades. Ini-
tially, these efforts were primarily aimed at blocking energy 
production, to which tumor cells were thought to be addicted. 
Increasingly, researchers have realized that tumor cells may 
not per se depend on metabolic flux, but rather may depend 
on anabolic pathways for the production of biomolecules such 
as nucleotides, amino acids, and fatty acids (Vander Heiden et 
al., 2009). The study by Qu et al. (2017) extends this view and 
shows that modulation of glycolytic pathways also affects sec-
ondary pathways that may be essential for tumor cell survival. 
PGAM1 inhibition interferes with nucleoside biosynthesis and 
through this mechanism induces HR deficiency. Based on this 
model, targeting of any enzymatic step involved in nucleoside 
synthesis may impact HR. Several lines of evidence indeed un-
derscore this model. For instance, the activity of phosphoinos-
itide 3-kinase is required for nucleoside synthesis (Juvekar et 
al., 2016). Accordingly, inhibition of phosphoinositide 3-kinase 
interfered with nucleoside synthesis and potently sensitized 
tumor cells for PARP inhibitor treatment (Juvekar et al., 2012). 
What remains difficult in these studies, however, is to identify to 
what extent the synergistic effects can be attributed to defective 
DNA repair, rather than interference with energy homeostasis 
or prosurvival signaling.
The observation by Qu et al. (2017) that PGAM1 inhibi-
tion blocks HR DNA repair clearly demonstrates that targeting 
metabolism may come with additional benefits, which can be 
exploited to further improve cancer treatment. These important 
insights set the stage for novel combination therapies. Future 
studies, however, will be required to establish which component 
of glycolysis (e.g., PGAM1/2) or PPP pathway (e.g., 6-phos-
phogluconate dehydrogenase) is the most effective therapeu-
tic target to inactivate HR DNA repair, and whether combined 
targeting of these enzymes may further impair HR and lead 
to more potent sensitization to DNA damaging agents. In this 
respect, it is important to realize that ongoing proliferation is 
required for many genotoxic agents to cause DNA lesions, in-
cluding PARP inhibitors and cisplatin. Targeting metabolism to 
sensitize tumors for DNA damaging agents may therefore re-
quire a well-balanced approach in which metabolism is affected 
sufficiently to induce a DNA repair defect, but still allows can-
cer cells to accumulate the relevant DNA lesions. When such 
features are established, these novel therapeutic approaches 
may extend the elegibility for PARP inhibitors beyond tumors 
with BRCA1/2 mutations. Alternatively, inhibition of PGAM1 
or related metabolic enzymes may be used to sensitize tumors 
for currently used chemotherapeutics, such as cisplatin, that 
also differentially affect HR-deficient cancers.
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